https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18982 Wed 11 Apr 2018 10:20:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15891 Wed 11 Apr 2018 10:15:38 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44516 95% of fractions were successfully delivered. The secondary outcomes were (1) the improvement in beam-target geometric alignment, (2) the improvement in dosimetric coverage of the prostate and avoidance of critical structures, and (3) no acute grade ≥3 genitourinary or gastrointestinal toxicity. Results: All 858 planned fractions were successfully delivered with MLC tracking, demonstrating the primary outcome of feasibility (P < .001). MLC tracking improved the beam-target geometric alignment from 1.4 to 0.90 mm (root-mean-square error). MLC tracking improved the dosimetric coverage of the prostate and reduced the daily variation in dose to critical structures. No acute grade ≥3 genitourinary or gastrointestinal toxicity was observed. Conclusions: Electromagnetic-guided MLC tracking radiation therapy for prostate cancer is feasible. The patients received improved geometric targeting and delivered dose distributions that were closer to those planned than they would have received without electromagnetic-guided MLC tracking. No significant acute toxicity was observed.]]> Wed 09 Nov 2022 10:02:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39845 Tue 19 Jul 2022 08:45:26 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29628 Thu 27 Jan 2022 15:55:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21487 Sat 24 Mar 2018 08:03:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21062 Sat 24 Mar 2018 07:59:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39998 Fri 15 Jul 2022 11:01:56 AEST ]]>